Generic drug product application to cost Rs 30 lakh in US
   
Quotes

Generic drug product application to cost Rs 30 lakh in US

Last Updated: Wednesday, December 19, 2012, 16:40
 
 Comment 0
 
Generic drug product application to cost Rs 30 lakh in US
New Delhi: Indian generic drug exporters to US will have to pay about Rs 30 lakh (about USD 54,700) each as fee for every new product application they file with the US health regulator as per an amended law in that country, Parliament was informed on Wednesday.

This is as per the Generic Drug User Fee Amendments of 2012 (GDUFA) of the US government, Minister of State for Commerce and Industry D Purandeswari said in a written reply.

She said any company interested in supplying generic drugs with effect from October 1, 2012 have to pay the prescribed fee to the US Food and Drug Administration (FDA) for registering their products in the US.

"There will be financial impact on generic drug exports to USA as the exporters are now required to pay about Rs 30 lakh for registration of each abbreviated new drug application (ANDA)," Purandeswari said.

The companies would also have to pay about Rs 12 lakh for filing of Drug Master File (DMF) with the FDA, she added.

India currently supplies nearly 20 percent of the generic medicines in global market.

According to Department of Pharmaceuticals, the Indian pharma sector is expected to grow from its current level of Rs 1 lakh crore to Rs 5 lakh crore by 2020.

In 2010, the Indian pharma export business reached USD 10.3 billion and grew to touch a level of USD 13.3 billion in 2011. It is targeted to touch USD 25 billion by 2015.

PTI



First Published: Wednesday, December 19, 2012, 16:40


Comments


comments powered by Disqus
Ford Figo Aspire
Ford Figo Aspire
Samsung Galaxy S6 Edge Plus, Note 5
Samsung Galaxy S6 Edge Plus, Note 5
Maruti Suzuki S-Cross
Maruti Suzuki S-Cross
Mahindra New Thar CRDe
Mahindra New Thar CRDe
New Generation Scorpio
New Generation Scorpio

Contact Us : Privacy Policy : Legal Disclaimer
Copyright © Zee Media Corporation Ltd. All rights reserved